Akums Drugs and Pharmaceuticals Ltd., a Contract Development and Manufacturing Organization (CDMO), has announced the launch of Doxylamine + Pyridoxine extended-release tablets, a therapy approved by the CSDCO (Central Drugs Standard Control Organization), India and the United States Food and Drug Administration (USFDA). This marks a milestone as a therapy in India, with a [patent application in process]. Akums’ inventive solution aims to tackle the issues by integrating Doxylamine and Pyridoxine into extended-release tablets.
Akums, Lyrus Life Sciences collaborate for patented technologies and formulations
Akums receives DCGI approval for type 2 diabetes drug to improve insulin resistance
New Delhi: Leading contract manufacturing drug firm Akums Drugs & Pharmaceuticals plans to expand its presence globally and enhance product range as it looks to more than double its turnover to Rs 10,000 crore by 2028, as per the company's Joint Managing Director Sandeep Jain. The company, which produces around 12 per cent of all the medicines consumed in the country from its 15 manufacturing facilities, has a topline of about Rs 4,000 crore currently.